Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
Atea Pharmaceuticals (Nasdaq: AVIR) announced it will host a conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to discuss third quarter 2024 financial results and provide a business update. The event will be accessible via telephone registration and webcast through the company's investor relations website. An archive of the webcast will be available for at least 90 days following the event.
Atea Pharmaceuticals (Nasdaq: AVIR) ha annunciato che ospiterà una conference call e un webcast audio giovedì 7 novembre 2024, alle 16:30 ET, per discutere i risultati finanziari del terzo trimestre 2024 e fornire un aggiornamento commerciale. L'evento sarà accessibile tramite registrazione telefonica e webcast attraverso il sito web delle relazioni con gli investitori dell'azienda. Un archivio del webcast sarà disponibile per almeno 90 giorni dopo l'evento.
Atea Pharmaceuticals (Nasdaq: AVIR) anunció que realizará una llamada de conferencia y un webcast de audio el jueves 7 de noviembre de 2024, a las 4:30 p.m. ET, para discutir los resultados financieros del tercer trimestre de 2024 y proporcionar una actualización del negocio. El evento será accesible a través de la inscripción telefónica y el webcast a través del sitio web de relaciones con inversionistas de la empresa. Un archivo del webcast estará disponible durante al menos 90 días después del evento.
Atea Pharmaceuticals (Nasdaq: AVIR)는 2024년 11월 7일 목요일 오후 4시 30분 ET에 2024년 3분기 재무 결과를 논의하고 사업 업데이트를 제공하기 위한 전화 회의 및 오디오 웹캐스트를 주최한다고 발표했습니다. 이 행사는 회사 투자자 관계 웹사이트를 통해 전화 등록 및 웹캐스트를 통해 접근할 수 있습니다. 웹캐스트의 아카이브는 이벤트 후 최소 90일 동안 이용 가능합니다.
Atea Pharmaceuticals (Nasdaq: AVIR) a annoncé qu'elle tiendra une conférence téléphonique et un webinaire audio le jeudi 7 novembre 2024, à 16h30 ET, pour discuter des résultats financiers du troisième trimestre 2024 et fournir une mise à jour sur l'entreprise. L'événement sera accessible par inscription téléphonique et webinaire via le site Internet des relations investisseurs de l'entreprise. Un archive du webinaire sera disponible pendant au moins 90 jours après l'événement.
Atea Pharmaceuticals (Nasdaq: AVIR) gab bekannt, dass am Donnerstag, den 7. November 2024, um 16:30 Uhr ET eine Telefonkonferenz und ein Audiowebcast stattfinden werden, um die finanziellen Ergebnisse des dritten Quartals 2024 zu erörtern und ein Unternehmensupdate zu geben. Die Veranstaltung ist über telefonische Registrierung und Webcast auf der Website für Investorenbeziehungen des Unternehmens zugänglich. Ein Archiv des Webcasts wird mindestens 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business update.
To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archive of the audio webcast will be available on Atea’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Our lead program and current focus is on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat hepatitis C virus. For more information, please visit
www.ateapharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the Company’s plans relating to the date and time of the anticipated conference call and audio webcast. When used herein, words including “may,” “will,” “anticipates,” “plans,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption “Risk Factors” in the reports the Company files with the SEC, including annual reports on Form10-K, quarterly reports on Form10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
Will O’Connor
Precision AQ
212-362-1200
will.oconnor@precisionaq.com
FAQ
When will Atea Pharmaceuticals (AVIR) report Q3 2024 earnings?
How can investors access Atea Pharmaceuticals' (AVIR) Q3 2024 earnings call?